T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer.

Cancers (Basel) · 2022 · PMC9139620 · PMID 35626072

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In EMILIA, median progression-free survival (PFS) and overall survival (OS) were significantly longer with T-DM1 versus lapatinib plus capecitabine [ 3 ]; in TH3RESA, median PFS was significantly improved and median OS showed a trend toward improvement with T-DM1 versus physician’s choice [ 4 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.